Koers PharmaRoth Labs, Inc. Other OTC
Aandelen
ROTH
US71715Y1029
Farmaceutische producten
Omzet 2009 | - | Omzet 2010 | - | Marktkapitalisatie | 5,74 mln. 5,35 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2009 | - 0 | Nettowinst (verlies) 2010 | - 0 | EV/omzet 2009 | - |
Nettoschuld 2009 | 12,5K 11,66K | Nettoschuld 2010 | 286K 267K | EV/omzet 2010 | - |
K/w-verhouding 2009 |
-777
x | K/w-verhouding 2010 |
-7,8
x | Werknemers | - |
Dividendrendement 2009 * |
-
| Dividendrendement 2010 |
-
| Vrij verhandelbaar | 30,93% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | - | 31-08-10 | |
Barry W. Hall
DFI | Director of Finance/CFO | 76 | 22-01-13 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | - | 31-08-10 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+26,47% | 664 mld. | |
+29,78% | 567 mld. | |
-6,33% | 354 mld. | |
+19,35% | 330 mld. | |
+4,23% | 286 mld. | |
+14,27% | 234 mld. | |
+5,01% | 199 mld. | |
-10,02% | 196 mld. | |
-4,04% | 148 mld. |